LAUSR

Sevoflurane (Sev) is a rapidly acting, potent inhalation anesthetic with rapid uptake and elimination. But many studies showed Sev could result in cognition dysfunction in adolescent or aging patients. Now, therapeutic targeting with IL-17A antibody showed a promising effect on Sev induced cognition impairment. In the study we reported that P300 inhibition could act as an alternative approach to decrease IL-17A activity. We found that P300 and IL-17A were activated in SHSY5Y cells treated with Sev. P300 inhibitor C646 could reduce the apoptosis induced by Sev through decreasing IL-17A avtivity. Furthermore, IL-17A expression was up-regulated after neurons were transfected with P300 expression plasmid and IL-17A expression was down-regulated after neurons were incubated with P300 inhibitor C646. P300 over-expression could up-regulate the promoter activity of IL-17A. Finally, in rat model treated with Sev, we also found C646 significantly improve the cognition impairment through IL-17A pathway. These data showed that P300 will potentially be a new drug target for the therapy of cognition impairment caused by Sev.